11/27 Marketwire - Medical and Healthcare

Please add updates@feedmyinbox.com to your address book to make sure you receive these messages in the future. Marketwire - Medical and Healthcare Diabetes Prevalence Expected to Double in Next 25 Years November 27, 2009 at 12:01 am Absent Major Changes, Cost Will Add Further Strain to Health System Horizon Health International Corp.-E-Commerce Website Update November 26, 2009 at 9:48 pm NORTH VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 26, 2009) - HORIZON HEALTH INTERNATIONAL CORP. (PINK SHEETS:HZHI) (The Company) is pleased to confirm that the previously announced e-commerce websites www.horizonhealthandsafety-canada.com (formerly: www.medichair-calgary.com), for the Canadian customers and, www.horizonhealthandsafety-usa.com for the US customers are NOW OPERATIONAL. BioSyent Releases 2009 Third Quarter Financial Results November 26, 2009 at 4:06 pm MISSISSAUGA, ONTARIO--(Marketwire - Nov. 26, 2009) - BioSyent Inc. ("BioSyent")(TSX VENTURE:RX) today released a summary of its 2009 third quarter financial results. During the third quarter ended September 30, 2009 sales increased by 17%, from $431,841 in the third quarter of 2008 to $540,870 in the third quarter of 2009. Total Sales fell by 5% from $956,414 in the first nine months of 2008 to $911,543 in the first nine months of 2009. The first nine months were impacted by general recessionary conditions in the economy. Information Update: Important Information on Changes to Heparin Potency November 26, 2009 at 12:21 pm OTTAWA, ONTARIO--(Marketwire - Nov. 26, 2009) - Health Canada is informing health care professionals and Canadians of recent changes to heparin manufacturing standards in the United States that will result in a decrease in the potency of certain heparin products by about 10 per cent. Heparin is a common anti-clotting drug mainly used in health care settings such as hospitals. It is used, for example, as part of kidney dialysis or to prevent blood clots. Most heparin products on the Canadian market use the same potency standard as is used in the U.S. As a result, the changes to the U.S standard will also affect heparin products available in Canada. Mise à jour : Information importante concernant des modifications à la puissance de l'héparine November 26, 2009 at 12:21 pm OTTAWA, ONTARIO--(Marketwire - 26 nov. 2009) - Santé Canada avise les professionnels de la santé et les Canadiens des récentes modifications apportées aux normes de fabrication de l'héparine aux Etats-Unis. Ces changements se traduiront par une diminution d'environ 10 % de la puissance de certains produits d'héparine. L'héparine est un médicament anticoagulant d'usage courant principalement utilisé dans des établissements de soins de santé comme les hôpitaux. L'héparine sert entre autres aux dialyses rénales ou à prévenir la formation de caillots sanguins. La majorité des produits d'héparine sur le marché canadien respectent la même norme de puissance que celle en vigueur aux Etats-Unis. Par conséquent, les modifications apportées à la norme américaine toucheront également les produits d'héparine distribués au Canada.   This email was sent to billionlys.asdf1234@blogger.com.  Manage Your Account Don't want to receive this feed any longer? Unsubscribe here.